Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study)

References

• Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;388:853–860.
   Web of Science ®Google Scholar
• Palella FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34.
   PubMed Web of Science ®Google Scholar
• Puhan MA, Van Natta ML, Palella FJ, et al. Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factors. Clin Infect Dis. 2010;51:947–956.
   PubMed Web of Science ®Google Scholar
• Nou E, Lo J, Grinspoon SK. Inflammation, immune activation, and cardiovascular disease in HIV. AIDS. 2016;30:1495–1509.
   PubMed Web of Science ®Google Scholar
• Kaplan RC, Hanna DB, Kizer JR. Recent insights into cardiovascular disease (CVD) risk among HIV-infected adults. Curr HIV/AIDS Rep. 2016;13:44–52.
   PubMed Web of Science ®Google Scholar
• Feinstein MJ, Bahiru E, Achenbach C, et al. Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013. Am J Cardiol. 2016;117:214–220.
   PubMed Web of Science ®Google Scholar
• Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis. 2000;32:111–123.
   PubMed Web of Science ®Google Scholar
• Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis. 2007;7:787–796.
   PubMed Web of Science ®Google Scholar
• Nduka C, Sarki A, Uthman O, et al. Impact of antiretroviral therapy on serum lipoprotein levels and dyslipidemias: a systematic review and meta-analysis. Int J Cardiol. 2015;199:307–318.
   PubMed Web of Science ®Google Scholar
• Young J, Weber R, Rickenbach M, et al. Lipid profiles for antiretroviral-naïve patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther. 2005;10:585–591.
   PubMed Web of Science ®Google Scholar
• Randell PA, Jackson AG, Boffito M, et al. Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men. Antivir Ther (Lond). 2010;15:1125–1132.
   PubMed Web of Science ®Google Scholar
• Overton ET, Arathoon E, Baraldi E, et al. Effect of darunavir on lipid profile in HIV-infected patients. HIV Clin Trials. 2012;13:256–270.
   PubMed Web of Science ®Google Scholar
• Quercia R, Roberts J, Martin-Carpenter L, et al. Comparative changes of lipid levels in treatment-naïve, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig. 2015;35:211–219.
   PubMed Web of Science ®Google Scholar
• Calza L, Colangeli V, Manfredi R, et al. Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother. 2016;71:1451–1465.
   PubMed Web of Science ®Google Scholar
• Myerson M, Malvestutto C, Aberg JA. Management of lipid disorders in patients living with HIV. J Clin Pharmacol. 2015;55:957–974.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1–S45.
   PubMed Web of Science ®Google Scholar
• Negredo E, Paredes R, Bonjoch A, et al. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up. Antivir Ther. 1999;4(Suppl 3):23–28.
   PubMed Web of Science ®Google Scholar
• Echeverria P, Bonjoch A, Puig J, et al. Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study. PLoS One. 2014;9:e84676.
   PubMed Web of Science ®Google Scholar
• Palella FJ, Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 2014;28:335–344.
   PubMed Web of Science ®Google Scholar
• Gazaignes S, Resche-Rigon M, Gatey C, et al. Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study. Antivir Ther. 2015;17(4 Suppl 3):19796.
   Google Scholar
• Baril JG, Angel JB, Gill MJ, et al. Dual therapy treatment strategies for the management of patients infected with HIV: a systematic review of current evidence in ARV-naive or ARV-experienced, virologically suppressed patients. PLoS One. 2016;11:e0148231.
   PubMed Web of Science ®Google Scholar
• Blanco JL, Martinez-Picado J. HIV integrase inhibitors in ART-experienced patients. Curr Opin HIV AIDS. 2012;7:415–421.
   PubMed Web of Science ®Google Scholar
• Fisac C, Virgili N, Ferrer E, et al. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study. J Clin Endocrinol Metab. 2003;88:5186–5192.
   PubMed Web of Science ®Google Scholar
• Van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004;1:e19.
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Andrade-Villanueva J, Clotet B, et al. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). HIV Med. 2011;12:374–382.
   PubMed Web of Science ®Google Scholar
• Franssen R, Sankatsing R, Hassink E, et al. Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol. 2009;29:1336–1341.
   PubMed Web of Science ®Google Scholar
• Podzamczer D. Lipid metabolism and cardiovascular risk in HIV infection: new perspectives and the role of nevirapine. AIDS Rev. 2013;15:195–203.
   PubMed Web of Science ®Google Scholar
• Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375:396–407.
   PubMed Web of Science ®Google Scholar
• Martinez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;24:1697–1707.
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Mondi A, Colafigli M, et al. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). Scand J Infect Dis. 2014;46:34–45.
   PubMed Web of Science ®Google Scholar
• Martinez E, D’Albuquerque PM, Llibre JM, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS. 2012;26:2315–2326.
   PubMed Web of Science ®Google Scholar
• Lake JE, McComsey GA, Hulgan T, et al. Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial. HIV Med. 2014;15:431–441.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Pialoux G, Gathe J, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis. 2014;14:581–589.
   PubMed Web of Science ®Google Scholar
• Gili S, Grosso Marra W, D’Ascenzo F, et al. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. Eur Heart J. 2016;37:3600–3609.
   PubMed Web of Science ®Google Scholar
• Calza L, Trapani F, Bartoletti M, et al. Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in HIV-infected patients treated with ritonavir-boosted protease inhibitors. HIV Clin Trials. 2012;13:153–161.
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Colangeli V, et al. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk. AIDS Res Hum Retroviruses. 2013;29:547–556.
   PubMed Web of Science ®Google Scholar
• Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;68:396–404.
   PubMed Web of Science ®Google Scholar
• Longenecker CT, Sattar A, Gilkeson R, et al. Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection. AIDS. 2016;30:2195–2203.
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Colangeli V, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS. 2005;19:1051–1058.
   PubMed Web of Science ®Google Scholar
• Lee FJ, Monteiro P, Baker D, et al. Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial. HIV Med. 2016;17:605–614.
   PubMed Web of Science ®Google Scholar